Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan.

OBJECTIVE In this study, we attempted to describe and justify the use of a contingent valuation (CV) method to elicit the willingness to pay (WTP) for a drug abuse treatment program by the general public in Taiwan. METHOD In total, 1817 CV survey questionnaires were conducted through telephone interviews from randomly dialed numbers. Subjects were members of the general public aged between 20 and 65 years, with full-time jobs, and residing in the three major Taiwanese cities of Taipei, Taichung, and Kaohsiung. Respondents' WTP for drug treatment programs was elicited for two different financing mechanisms: payment through 'compulsory' payroll tax/health insurance premiums, and through 'voluntary' donations. The WTP was modeled as a function of scenarios and policies of the treatment program, respondents' socio-demographic information, and their responses to knowledge and attitudes questions. RESULTS The general public in Taiwan was estimated to be willing to pay between NT$81.00 and NT$95.00 per month for a drug abuse treatment program, while the benefits of drug abuse treatment were estimated to range between NT$12.8 billion and NT$15.0 billion in 2004 (US$1=NT$31.9 in 2004), which was equal to around 0.15% of Taiwan's GDP for that year. The general public in Taiwan was more willing to pay for drug abuse treatment via increases in NHI premiums than via donations. Preferences for the drug abuse treatment program were also found to be sensitive to the target treated population as well as the sequence in which the WTP questions were asked. CONCLUSIONS Results of this study provide policymakers with important evidence on the monetary value of a substance abuse treatment program, allocation of healthcare resources, and a possible financing mechanism of the treatment program, which may be justified by knowledge of the WTP of the general public. This study has also advanced the knowledge of the methodological issues with regard to CV questionnaire design, and it provides a base case for further studies on drug abuse in Taiwan.

[1]  U. Persson,et al.  Scope and scale insensitivities in a contingent valuation study of risk reductions. , 2001, Health policy.

[2]  T. Mark,et al.  The economic costs of heroin addiction in the United States. , 2001, Drug and alcohol dependence.

[3]  Robert A. Young,et al.  Recreational Demands for Maintaining Instream Flows: A Contingent Valuation Approach , 1981 .

[4]  Emma Frew,et al.  A comparison of two methods for eliciting contingent valuations of colorectal cancer screening. , 2003, Journal of health economics.

[5]  M Johannesson,et al.  Value for money? A contingent valuation study of the optimal size of the Swedish health care budget. , 1995, Health policy.

[6]  Economic value of a local museum: Factors of willingness-to-pay , 2004 .

[7]  David K Whynes,et al.  Comparing willingness-to-pay: bidding game format versus open-ended and payment scale formats. , 2004, Health policy.

[8]  M. Johannesson,et al.  Willingness to pay for antihypertensive therapy--results of a Swedish pilot study. , 1991, Journal of health economics.

[9]  C. Donaldson,et al.  Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. , 1998, Social science & medicine.

[10]  A. Gafni.  Using willingness-to-pay as a measure of benefits , 1990 .

[11]  D. H. Day,et al.  Willingness to pay for water quality maintenance in Chinese rivers , 1998 .

[12]  M Johannesson,et al.  Valuation of health changes with the contingent valuation method: a test of scope and question order effects. , 1996, Health economics.

[13]  T Klose,et al.  The contingent valuation method in health care. , 1999, Health policy.

[14]  M. Johannesson,et al.  Willingness to pay for antihypertensive therapy--further results. , 1993, Journal of health economics.

[15]  I. Osei-Akoto,et al.  Willingness to pay for health insurance in a developing economy. A pilot study of the informal sector of Ghana using contingent valuation. , 1997, Health policy.

[16]  T. Wagner,et al.  Does willingness to pay vary by race/ethnicity? An analysis using mammography among low-income women. , 2001, Health policy.

[17]  M. Johannesson,et al.  Patients' willingness to pay for autologous blood donation. , 1997, Health policy.

[18]  R. Young,et al.  Option Value: Empirical Evidence from a Case Study of Recreation and Water Quality , 1981 .

[19]  A Gafni,et al.  Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs. , 1991, Medical care.

[20]  W. Shyu,et al.  The willingness of families caring for victims of stroke to pay for in-home respite care--results of a pilot study in Taiwan. , 1999, Health policy.

[21]  The Citizen's Preferences for Financing Public Health Care: A Danish Survey , 2004, International Journal of Health Care Finance and Economics.

[22]  Baruch Fischhoff,et al.  Scope (in)sensitivity in elicited valuations , 1998 .

[23]  P. Reuter.  World drug report , 1998 .

[24]  R. Sauerborn,et al.  Differential willingness of household heads to pay community-based health insurance premia for themselves and other household members. , 2004, Health policy and planning.

[25]  F. Antoñanzas,et al.  The social cost of illegal drug consumption in Spain. , 2002, Addiction.

[26]  Richard C. Ausness,et al.  Reclaiming Coal Surface Mines in Central Appalachia: A Case Study of the Benefits and Costs , 1978 .

[27]  M. Bala,et al.  Estimating the willingness to pay for drug abuse treatment: a pilot study. , 2000, Journal of substance abuse treatment.

[28]  L. Lenert.  Use of Willingness to Pay to Study Values for Pharmacotherapies for Migraine Headache , 2003, Medical care.

[29]  A Gafni,et al.  Health care contingent valuation studies: a review and classification of the literature. , 1998, Health economics.

[30]  K. Foreit,et al.  The reliability and validity of willingness to pay surveys for reproductive health pricing decisions in developing countries. , 2003, Health policy.

[31]  L. Robson,et al.  The economic costs of illicit drug use in Ontario, 1992. , 1998, Health economics.

[32]  D. Cohen,et al.  Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. , 2004, Health policy.